Analysts Set C4 Therapeutics, Inc. (NASDAQ:CCCC) Price Target at $10.00

Shares of C4 Therapeutics, Inc. (NASDAQ:CCCC) have been assigned a consensus rating of “Hold” from the six analysts that are currently covering the company, MarketBeat reports. Four equities research analysts have rated the stock with a hold rating and two have issued a buy rating on the company. The average 12-month price objective among analysts that have updated their coverage on the stock in the last year is $10.00.

CCCC has been the topic of a number of recent research reports. Stephens began coverage on C4 Therapeutics in a research report on Monday, November 18th. They issued an “equal weight” rating and a $4.00 target price on the stock. BMO Capital Markets reaffirmed an “outperform” rating and issued a $20.00 price objective on shares of C4 Therapeutics in a report on Tuesday, August 6th.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. Franklin Resources Inc. purchased a new position in shares of C4 Therapeutics during the 3rd quarter valued at approximately $202,000. Barclays PLC raised its position in shares of C4 Therapeutics by 38.4% in the third quarter. Barclays PLC now owns 243,457 shares of the company’s stock worth $1,387,000 after acquiring an additional 67,546 shares during the period. Geode Capital Management LLC boosted its stake in shares of C4 Therapeutics by 0.5% during the 3rd quarter. Geode Capital Management LLC now owns 1,369,676 shares of the company’s stock worth $7,809,000 after acquiring an additional 7,460 shares in the last quarter. Vestcor Inc purchased a new position in C4 Therapeutics during the third quarter worth approximately $168,000. Finally, M&T Bank Corp grew its holdings in C4 Therapeutics by 19.3% in the third quarter. M&T Bank Corp now owns 113,907 shares of the company’s stock valued at $649,000 after purchasing an additional 18,466 shares during the period. 78.81% of the stock is owned by institutional investors and hedge funds.

C4 Therapeutics Trading Up 8.6 %

Shares of C4 Therapeutics stock opened at $4.55 on Monday. The firm’s 50 day simple moving average is $5.56 and its two-hundred day simple moving average is $5.60. The firm has a market capitalization of $321.18 million, a price-to-earnings ratio of -2.68 and a beta of 3.04. C4 Therapeutics has a 12-month low of $1.06 and a 12-month high of $11.88.

C4 Therapeutics (NASDAQ:CCCC) last issued its earnings results on Thursday, October 31st. The company reported ($0.35) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.40) by $0.05. The company had revenue of $15.36 million during the quarter, compared to analyst estimates of $5.95 million. C4 Therapeutics had a negative return on equity of 42.45% and a negative net margin of 313.35%. On average, sell-side analysts predict that C4 Therapeutics will post -1.48 EPS for the current fiscal year.

C4 Therapeutics Company Profile

C4 Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials.